CGA (400 mg/kg/day) can decrease the lesional areas of atherosclerosis in ApoE−/− mice by activating the PPARγ–liver X receptor α (LXRα)–ATP-binding cassette transporter A1 (ABCA1) signaling [86,87]. Here, ABCA1 is linked to atherosclerosis.